First, we used the METABRIC cohort to investigate the possible correlation between mRNA and clinical outcome; this analysis revealed that patients with SLC7A5+SLC3A2+ tumours had a significantly worse recurrence, distant metastasis and shorter survival (p = 0.01; Figure 3A–C) compared to other subgroups. Here, SLC7A5 is linked to neoplasm.